There has been a multitude of high-profile failures in Alzheimer’s drugs, but now, there is renewed optimism that the progress of the disease can be slowed.

Image Credit

While numerous voluntary and paid research studies haven’t yielded the desired results, a new drug has shown to improve cognition and to reduce the signs of Alzheimer’s in the participants’ brains. After so many past failures, no one wants to shout that a cure has suddenly been found, but experts are hopeful that the results can be reproduced in future clinical trials.

A miracle drug?

The drug that has shown good results is called BAN2401 and it not only reduced the formation of beta-amyloid clusters newly forming on the brain but reduced all existing clusters by approximately 70%. It’s this build up of beta-amyloid within the brain that is the hallmark of Alzheimer’s and being able to reduce it, remove it or stop it altogether is a key step in treating the disease as a whole.

The drug trials and the paid research studies are being undertaken by Biogen, and a Japanese drugmaker Eisai, and they jointly announced the positive results recently. Should the next stage of trials prove successful, they may look at something like 
Paid Research Studies by Trials4us or similar, to take the testing to the next phase.

Positive results

In addition to the reduction and elimination of beta-amyloid clusters on the brain, BAN2401 also showed a 26-30% benefit when compared to a placebo in improving cognition in the trial subjects.

Image Credit

At the 2018 Alzheimer's Association International Conference in Chicago, researchers elaborated on the drug and its success and said that the trial subjects were those who were in the early stages of Alzheimer’s and were forgetting things like people’s names and suffering from mild confusion, and this was the target group they wanted to help.

Chief clinical and medical officer for Eisai, Dr. Lynn Kramer, said that what had been achieved was the goal they were striving for, as they wanted to help those in the early stages of the disease and to stop it at its mildest presentation. He added that it was early days still, but the results gave them the incentive to keep trying to beat what has become an increasingly prevalent disease.